The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone
- 1 September 1998
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 78 (6), 774-776
- https://doi.org/10.1038/bjc.1998.577
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patientsBlood, 1996
- Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine onlyAmerican Journal Of Medicine, 1996
- Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.Proceedings of the National Academy of Sciences, 1995
- VAD chemotherapy as remission induction for multiple myelomaBritish Journal of Cancer, 1995
- Primary systemic amyloidosis: clinical and laboratory features in 474 cases.1995
- DIAGNOSTIC RADIONUCLIDE IMAGING OF AMYLOID: BIOLOGICAL TARGETING BY CIRCULATING HUMAN SERUM AMYLOID P COMPONENTThe Lancet, 1988
- [Treatment of AL amyloidosis without myeloma].1988
- Primary amyloidosis associated with multiple myeloma. Predictors of successful therapyAmerican Journal Of Medicine, 1986
- Amyloidosis (AL). Clinical and laboratory features in 229 cases.1983
- Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocolAmerican Journal Of Medicine, 1977